Cisplatin inhibits bone healing during distraction osteogenesis. 2014

Kimo C Stine, and Elizabeth C Wahl, and Lichu Liu, and Robert A Skinner, and Jacquelyn Vanderschilden, and Robert C Bunn, and Corey O Montgomery, and Larry J Suva, and James Aronson, and David L Becton, and Richard W Nicholas, and Christopher J Swearingen, and Charles K Lumpkin
Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, Arkansas.

Osteosarcoma (OS) is the most common malignant bone tumor affecting children and adolescents. Many patients are treated with a combination of chemotherapy, resection, and limb salvage protocols. Surgical reconstructions after tumor resection include structural allografts, non-cemented endoprostheses, and distraction osteogenesis (DO), which require direct bone formation. Although cisplatin (CDP) is extensively used for OS chemotherapy, the effects on bone regeneration are not well studied. The effects of CDP on direct bone formation in DO were compared using two dosing regimens and both C57BL/6 (B6) and tumor necrosis factor receptor 1 knockout (TNFR1KO) mice, as CDP toxicity is associated with elevated TNF levels. Detailed evaluation of the five-dose CDP regimen (2 mg/kg/day), demonstrated significant decreases in new bone formation in the DO gaps of CDP treated versus vehicle treated mice (p < 0.001). Further, no significant inhibitory effects from the five-dose CDP regimen were observed in TNFR1KO mice. The two-dose regimen significantly inhibited new bone formation in B6 mice. These results demonstrate that CDP has profound short term negative effects on the process of bone repair in DO. These data provide the mechanistic basis for modeling peri-operative chemotherapy doses and schedules and may provide new opportunities to identify molecules that spare normal cells from the inhibitory effects of CDP.

UI MeSH Term Description Entries
D008297 Male Males
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D001861 Bone Regeneration Renewal or repair of lost bone tissue. It excludes BONY CALLUS formed after BONE FRACTURES but not yet replaced by hard bone. Osteoconduction,Bone Regenerations,Regeneration, Bone,Regenerations, Bone
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha
D047888 Receptors, Tumor Necrosis Factor, Type I A tumor necrosis factor receptor subtype that has specificity for TUMOR NECROSIS FACTOR ALPHA and LYMPHOTOXIN ALPHA. It is constitutively expressed in most tissues and is a key mediator of tumor necrosis factor signaling in the vast majority of cells. The activated receptor signals via a conserved death domain that associates with specific TNF RECEPTOR-ASSOCIATED FACTORS in the CYTOPLASM. Antigens, CD120a,CD120a Antigens,Receptors, Tumor Necrosis Factor, Member 1A,Tumor Necrosis Factor Receptor Superfamily, Member 1A,Tumor Necrosis Factor Receptor Type I,CD 120a Antigen,CD120a Antigen,TNFR p60,TNFR-I,TNFR1,TNFRSF1A (Tumor Necrosis Factor Receptor Superfamily, Member 1A),TNFRSF1A Receptor,Tumor Necrosis Factor Receptor 1A,Tumor Necrosis Factor Receptor Type 1,120a Antigen, CD,Antigen, CD 120a,Antigen, CD120a,Receptor, TNFRSF1A
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus
D018345 Mice, Knockout Strains of mice in which certain GENES of their GENOMES have been disrupted, or "knocked-out". To produce knockouts, using RECOMBINANT DNA technology, the normal DNA sequence of the gene being studied is altered to prevent synthesis of a normal gene product. Cloned cells in which this DNA alteration is successful are then injected into mouse EMBRYOS to produce chimeric mice. The chimeric mice are then bred to yield a strain in which all the cells of the mouse contain the disrupted gene. Knockout mice are used as EXPERIMENTAL ANIMAL MODELS for diseases (DISEASE MODELS, ANIMAL) and to clarify the functions of the genes. Knockout Mice,Mice, Knock-out,Mouse, Knockout,Knock-out Mice,Knockout Mouse,Mice, Knock out

Related Publications

Kimo C Stine, and Elizabeth C Wahl, and Lichu Liu, and Robert A Skinner, and Jacquelyn Vanderschilden, and Robert C Bunn, and Corey O Montgomery, and Larry J Suva, and James Aronson, and David L Becton, and Richard W Nicholas, and Christopher J Swearingen, and Charles K Lumpkin
December 2009, Clinical orthopaedics and related research,
Kimo C Stine, and Elizabeth C Wahl, and Lichu Liu, and Robert A Skinner, and Jacquelyn Vanderschilden, and Robert C Bunn, and Corey O Montgomery, and Larry J Suva, and James Aronson, and David L Becton, and Richard W Nicholas, and Christopher J Swearingen, and Charles K Lumpkin
August 2011, Injury,
Kimo C Stine, and Elizabeth C Wahl, and Lichu Liu, and Robert A Skinner, and Jacquelyn Vanderschilden, and Robert C Bunn, and Corey O Montgomery, and Larry J Suva, and James Aronson, and David L Becton, and Richard W Nicholas, and Christopher J Swearingen, and Charles K Lumpkin
February 2008, Journal of dental research,
Kimo C Stine, and Elizabeth C Wahl, and Lichu Liu, and Robert A Skinner, and Jacquelyn Vanderschilden, and Robert C Bunn, and Corey O Montgomery, and Larry J Suva, and James Aronson, and David L Becton, and Richard W Nicholas, and Christopher J Swearingen, and Charles K Lumpkin
January 2022, Frontiers in bioengineering and biotechnology,
Kimo C Stine, and Elizabeth C Wahl, and Lichu Liu, and Robert A Skinner, and Jacquelyn Vanderschilden, and Robert C Bunn, and Corey O Montgomery, and Larry J Suva, and James Aronson, and David L Becton, and Richard W Nicholas, and Christopher J Swearingen, and Charles K Lumpkin
July 2009, Odontology,
Kimo C Stine, and Elizabeth C Wahl, and Lichu Liu, and Robert A Skinner, and Jacquelyn Vanderschilden, and Robert C Bunn, and Corey O Montgomery, and Larry J Suva, and James Aronson, and David L Becton, and Richard W Nicholas, and Christopher J Swearingen, and Charles K Lumpkin
January 2013, Ortopedia, traumatologia, rehabilitacja,
Kimo C Stine, and Elizabeth C Wahl, and Lichu Liu, and Robert A Skinner, and Jacquelyn Vanderschilden, and Robert C Bunn, and Corey O Montgomery, and Larry J Suva, and James Aronson, and David L Becton, and Richard W Nicholas, and Christopher J Swearingen, and Charles K Lumpkin
January 2011, The Journal of international medical research,
Kimo C Stine, and Elizabeth C Wahl, and Lichu Liu, and Robert A Skinner, and Jacquelyn Vanderschilden, and Robert C Bunn, and Corey O Montgomery, and Larry J Suva, and James Aronson, and David L Becton, and Richard W Nicholas, and Christopher J Swearingen, and Charles K Lumpkin
January 2015, Acta orthopaedica et traumatologica turcica,
Kimo C Stine, and Elizabeth C Wahl, and Lichu Liu, and Robert A Skinner, and Jacquelyn Vanderschilden, and Robert C Bunn, and Corey O Montgomery, and Larry J Suva, and James Aronson, and David L Becton, and Richard W Nicholas, and Christopher J Swearingen, and Charles K Lumpkin
June 2008, Annals of the Royal Australasian College of Dental Surgeons,
Kimo C Stine, and Elizabeth C Wahl, and Lichu Liu, and Robert A Skinner, and Jacquelyn Vanderschilden, and Robert C Bunn, and Corey O Montgomery, and Larry J Suva, and James Aronson, and David L Becton, and Richard W Nicholas, and Christopher J Swearingen, and Charles K Lumpkin
July 2017, The Journal of craniofacial surgery,
Copied contents to your clipboard!